HERTFORDSHIRE, England and
PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global
pharmaceutical company Mylan N.V. (NASDAQ: MYL) today
announced that Executive Chairman Robert J.
Coury, together with President Rajiv
Malik will present at the BofA Securities Virtual Global
Healthcare Conference on Thursday, Sep. 17,
2020, at 10:05 a.m. ET/
3:05 p.m. BST. Upjohn's Group
President Michael Goettler and
Upjohn's Chief Financial Officer Sanjeev
Narula will also be in attendance. Coury, Goettler,
Malik and Narula will serve as future executive chairman, chief
executive officer, president and chief financial officer of
Viatris, respectively.
Interested parties can access a live webcast of the presentation
via the investor relations section of Mylan's website at
investor.mylan.com. An archived version also will be available
following the live presentation and can be accessed at the same
location for a limited time.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com
Forward-Looking Statements
This communication contains "forward-looking statements",
including statements about completing the proposed combination of
Upjohn Inc. ("Upjohn") and Mylan N.V. ("Mylan"), which will
immediately follow the proposed separation of the Upjohn business
(the "Upjohn Business") from Pfizer Inc. ("Pfizer") (the "proposed
transaction"). Forward looking statements may often be identified
by the use of words such as "will", "may", "could", "should",
"would", "project", "believe", "anticipate", "expect", "plan",
"estimate", "potential", "intend", "continue", "target", "seek" and
variations of these words or comparable words. Because
forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: ongoing challenges and uncertainties posed
by the COVID-19 pandemic for businesses and governments around the
world; the parties' ability to meet expectations regarding the
timing, completion and accounting and tax treatments of the
proposed transaction; the parties' ability to consummate the
proposed transaction; the conditions to the completion of the
proposed transaction not being satisfied or waived on the
anticipated timeframe or at all; the regulatory approvals required
for the proposed transaction not being obtained on the terms
expected or on the anticipated schedule or at all; and
uncertainties and matters beyond the control of management and
other factors described under "Risk Factors" in each of Pfizer's,
Upjohn's and Mylan's Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q and other filings with the Securities and Exchange
Commission ("SEC"). These risks, as well as other risks associated
with Mylan, the Upjohn Business, the combined company and the
proposed transaction are also more fully discussed in the
Registration Statement on Form S-4, as amended, which includes a
proxy statement/prospectus (as amended, the "Form S-4"), which was
filed by Upjohn with the SEC on October 25,
2019 and declared effective by the SEC on February 13, 2020, the Registration Statement on
Form 10, which includes an information statement (the "Form 10"),
which was filed by Upjohn with the SEC on June 12, 2020 and declared effective by the SEC
on June 30, 2020, a final information
statement furnished with the Current Report on Form 8-K filed by
Upjohn with the SEC on August 6, 2020
(the "Final Information Statement"), a definitive proxy statement,
which was filed by Mylan with the SEC on February 13, 2020 (the "Proxy Statement"), and a
prospectus, which was filed by Upjohn with the SEC on February 13, 2020 (the "Prospectus"). You can
access Pfizer's, Mylan's and Upjohn's filings with the SEC through
the SEC website at www.sec.gov or through Pfizer's or Mylan's
website, as applicable, and Pfizer and Mylan strongly encourage you
to do so. Except as required by applicable law, Pfizer, Mylan and
Upjohn undertake no obligation to update any statements herein for
revisions or changes after this communication is made.
Additional Information and Where to Find It
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. In connection with the proposed transaction, Upjohn and
Mylan have filed certain materials with the SEC, including, among
other materials, the Form S-4, Form 10 and Prospectus filed by
Upjohn and the Proxy Statement filed by Mylan. The Form S-4 was
declared effective on February 13,
2020 and the Proxy Statement and the Prospectus were first
mailed to shareholders of Mylan on or about February 14, 2020 to seek approval of the
proposed transaction. The Form 10 was declared effective on
June 30, 2020. The Final Information
Statement was made available to Pfizer stockholders on or about
August 6, 2020. Upjohn and Mylan
intend to file additional relevant materials with the SEC in
connection with the proposed transaction. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC CAREFULLY
AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT MYLAN, UPJOHN AND THE PROPOSED TRANSACTION. The
documents relating to the proposed transaction (when they are
available) can be obtained free of charge from the SEC's website at
www.sec.gov. These documents (when they are available) can also be
obtained free of charge from Mylan, upon written request to Mylan
or by contacting Mylan at (724) 514-1813 or
investor.relations@mylan.com or from Pfizer on Pfizer's internet
website at
https://investors.Pfizer.com/financials/sec-filings/default.aspx or
by contacting Pfizer's Investor Relations Department at (212)
733-2323, as applicable.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mylan-to-present-at-the-bofa-securities-virtual-global-healthcare-conference-301126728.html
SOURCE Mylan N.V.
